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Angiomyolipoma (AML) is a benign renal mass that can be treated with nephron sparing surgery or transarterial
embolization. Embolization has been favored due to efficacy and safety profile. This case demonstrates a pre
viously undocumented phenomenon of AML treated with transarterial embolization using Lipiodol® (Guerbet
LLC, Princeton, NJ) resulting in nephrolithiasis and retention of Lipiodol® two years after original embolization.
Although Lipiodol®-based embolization has not been shown to cause nephrolithiasis, it may have been the nidus
for stone formation, and this is an important potential complication worthy of further study.

1. Introduction
Renal angiomyolipomas (AMLs) are the most common benign solid
tumors of the kidney, and are comprised of dysmorphic blood vessels,
adipose tissue and smooth muscle.1 AMLs carry a high risk of aneurysm
formation and spontaneous hemorrhage especially with increasing AML
size. Four centimeters is a common size cut-off, above which interven
tion if often recommended given the elevated risk of spontaneous severe
retroperitoneal bleeding.1 Most AMLs are diagnosed incidentally on CT
imaging where they can be identified with the classic finding of a renal
mass with macroscopic fat. Treatment of symptomatic or large AMLs
originally included nephron sparing surgery (NSS); however, renal ar
tery embolization has become a more popular option due to its safety
profile, preservation of renal parenchyma, and shorter convalescence
period.
Renal AML angioembolization is associated with certain complica
tions, some expected and others rare, but severe. Most commonly, pa
tients can experience post-embolization syndrome comprised of
abdominal pain, cramping, fever, nausea, and vomiting due to release of
inflammatory modulators in response to the infarcted tissue, occurring
within 72 hours after embolization.1 Although exceedingly rare, embolic
events following transcatheter arterial chemoembolization (such as
done for liver tumors) have been reported, including cerebral Lipiodol®
embolism, which proved fatal.2
We report a case of a patient with no prior nephrolithiasis history

who underwent successful transarterial embolization of a renal AML
with an admixture of Lipiodol® and 98% dehydrated ethanol. Two years
later the patient was found to have developed new renal stones and
found to have evidence of original embolization agent, Lipiodol® pre
sent in renal collecting system.
2. Case presentation
A 58-year-old female with past medical history of hypothyroidism
and hyperlipidemia presented to the urology clinic in April 2018 after
intermittent episodes of gross hematuria and right flank pain over the
span of 6 months. Social history included 20 pack-year smoking history
with last use 25 years ago. Renal ultrasound was performed which
showed a large echogenic mass in the right kidney, concerning for
neoplasm. Subsequent contrast-enhanced CT confirmed a 7.6cm ×
7.2cm x 10.4cm macroscopic-fat containing mass consistent with an
AML (Fig. 1). Renal function was normal and there was no proteinuria.
Due to the symptomatic presentation and size of the AML, treatment was
recommended. The patient was referred to Interventional Radiology and
transarterial embolization was successfully performed using 4mL of 3:1
alcohol to Lipiodol® mixture in May 2018.
The patient had two years of unremarkable follow-up until summer
2020 when she developed gross hematuria. Upon presentation a CT was
obtained and showed progressive involution of the right AML with new
stone development including an obstructing 1.1cm stone at the right
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Fig. 1. Right AML measuring 7.4cm × 7.2cm x 10.4cm found on initial CT scan.

Fig. 2. CT scan obtained 2 years after successful transarterial embolization showing new 1.5 cm calculi in the superior pole of the right kidney as well as 1.1 cm
calcification in the right proximal ureter with mild hydronephrosis.

ureteropelvic junction, and a 1.5cm curvilinear right upper pole stone
(Fig. 2). The patient then underwent ureteroscopy, laser lithotripsy and
stone basketing. Intraoperative findings included two “shell” shaped
stones with floating pale yellow lipid-like material around them that
appeared to have surrounding small calcifications (Fig. 3). In addition,
the same lipid-like material was seen actively extruding into the col
lecting system. The stones were sent for chemical analysis, revealing
60% calcium oxalate monohydrate, 33% calcium oxalate dihydrate, 7%
calcium magnesium phosphate. The lipid-like material was sent for fluid
analysis but results were inconclusive. The patient has been symptom-,
stone-, and hematuria-free since the ureteroscopy and is currently
schedule for a follow-up renal ultrasound.

and AML anatomy and multiplicity, and renal function. In the presented
patient, the size, location of the AML, and patient preference led to the
decision to pursue renal angioembolization.
Lipiodol® is composed of iodine and ethyl esters of fatty acids from
poppyseed oil. It was developed in the early 1900s to assist in diagnostic
imaging for liver, lung, and lymphatic disease.3 Lipiodol® has been used
as a contrast agent during hysterosalpingography in adults, lymphog
raphy in adults and pediatrics, and selective hepatic intra-arterial use for
imaging tumors with known hepatocellular carcinoma.3 Lipiodol® was
first used for transarterial catheter embolization in the 1980s. Since
then, there have been case reports of pulmonary and cerebral embolism
resulting from inadvertent non-target injection or intravasation of
Lipiodol®.3
Although there have not been case reports of Lipiodol® transferring
to and remaining within the renal collecting system, Lipiodol® residue
has mimicked a calcified biliary stone following transarterial emboli
zation for hepatocellular carcinoma and caused occlusion of the com
mon bile duct.4 There have also been inflammatory complications when
Lipiodol® was used for galactography where it mimicked intraductal
microcalcifications seen on mammography even up to 6 years after the
procedure.5 Lipiodol® residues also persisted in duct ectasia 1 year after
galactography.5 Lipiodol® is known to remain in tissue for long periods
of time, but to our knowledge, there have not been prior reports of
Lipiodol® eroding or migrating into the renal collecting system. Since

3. Discussion
First-line treatment for asymptomatic small AMLs is usually active
surveillance. However, if they become symptomatic or large (>4cm),
proactive treatment is recommended to reduce the risk of severe,
spontaneous hemorrhage. Treatment in this setting often involves
minimally invasive NSS or selective arterial embolization. NSS has been
shown to preserve renal functioning over nephrectomy, while selective
arterial embolization has been associated with renal functional preser
vation and minimal blood loss.1 The ultimate treatment decision is one
of shared-decision making and depends on many factors including renal
2
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Fig. 3. Intraoperative findings of Lipiodol appearing substance demonstrating active secretion from renal paraenchyma (A), shell like calcifications seen (B), and
renal stone that was found with surrounding substance (C & D). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)

Lipiodol® is a weak sclerosant with the ability to corrode plastic sy
ringes, this property could lead to its entering into the collecting sys
tem.3 It is likely that the Lipiodol® in the collecting system resulted in a
supersaturated solution which contributes to the conditions needed for
renal stone formation. The favorable supersaturated solution and
microcalfications that were seen clustered on the embolization material
led us to infer that Lipiodol® acted as a nidus for the stone formation.
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We report a unique case of symptomatic nephrolithiasis development
with erosion of embolization material two years after renal AML
embolization with Lipiodol®. It appears that the Lipiodol® erosion into
the renal collecting system may have acted as a nidus for stone forma
tion. This is an important consideration for the patient, urologist, and
interventional radiologist when proceeding with selective embolization
for renal angiomyolipomas.
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